Literature DB >> 19320648

The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly.

N Karavitaki1, A Fernandez, V Fazal-Sanderson, J A H Wass.   

Abstract

BACKGROUND: The nadir GH value following an oral glucose tolerance test (OGTT) and the mean GH levels obtained from a GH day curve (GHDC) are among the tools currently used for assessing therapeutic end-points in surgically treated acromegaly. The latter test, however, is cumbersome and costly.
OBJECTIVES: To evaluate, by using a modern, two-site chemiluminescent immunometric GH assay, the degree of discordance between the nadir GH following an OGTT and the mean GH obtained from a GHDC after surgical treatment of acromegaly and to check whether the OGTT can replace reliably the GHDC for the assessment of the disease status postoperatively. PATIENTS AND METHODS: Forty-nine patients [25 males/24 females, median age 52 years (range 18-70)] with a GH-secreting pituitary adenoma who had been surgically treated previously underwent hormonal evaluation of their disease status. The GHDC comprised of 9 x 30-min samples for GH collected in the morning after an overnight fast and rest.
RESULTS: Seven per cent of patients with mean GH <1.7 mug/l (5 mU/l) in the GHDC had nadir GH >0.7 mug/l (2 mU/l) in the OGTT, and 10% of those with mean GH >1.7 mug/l had nadir GH <0.7 mug/l in the OGTT (all cases with discrepancies had normal IGF-I). GH value at time 0 min <0.6 mug/l in the OGTT had positive predictive value 100% and negative predictive value 75% in predicting nadir GH <0.3 mug/l (1 mU/l) in the OGTT. Nadir GH <0.8 mug/l in the OGTT had positive predictive value 97% and negative predictive value 95% in predicting mean GH <1.7 mug/l in the GHDC. Mean GH in the OGTT <1.4 mug/l had a positive predictive value 90% and negative predictive value 95% in predicting mean GH <1.7 mug/l in the GHDC. Mean GH in the OGTT <2.5 mug/l had positive predictive value 100% and negative predictive value 81% in predicting normal IGF-I. GH at time 0 min in the GHDC <2.1 mug/l had positive predictive value 90% and negative predictive value 90% in predicting mean GH <1.7 mug/l in the GHDC.
CONCLUSIONS: The hormonal data obtained from an OGTT (mean and nadir GH) can provide comprehensive information on the status of acromegaly following surgery and can replace the GHDC cost-effectively. Furthermore, a morning fasting GH sample has an excellent positive predictive value in predicting biochemical cure and an optimal prognostic profile in predicting "safe" mean GH levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19320648     DOI: 10.1111/j.1365-2265.2009.03578.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?

Authors:  Jessica A Brzana; Chris G Yedinak; Johnny B Delashaw; Hume S Gultelkin; David Cook; Maria Fleseriu
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

2.  Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients.

Authors:  Laura Boero; Marcos Manavela; Karina Danilowicz; Analia Alfieri; Maria Carolina Ballarino; Alberto Chervin; Natalia García-Basavilbaso; Mariela Glerean; Mirtha Guitelman; Monica Graciela Loto; Jose Alberto Nahmías; Amelia Susana Rogozinski; Marisa Servidio; Nicolas Marcelo Vitale; Débora Katz; Patricia Fainstein Day; Graciela Stalldecker; Maria Susana Mallea-Gil
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

3.  Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.

Authors:  Giuseppe Reimondo; Marta Bondanelli; Maria Rosaria Ambrosio; Franco Grimaldi; Barbara Zaggia; Maria Chiara Zatelli; Barbara Allasino; Federica Laino; Emiliano Aroasio; Angela Termine; Pierantonio Conton; Agostino Paoletta; Ernesto Demenis; Ettore Degli Uberti; Massimo Terzolo
Journal:  Endocrine       Date:  2013-06-21       Impact factor: 3.633

Review 4.  Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.

Authors:  Mehdi Zeinalizadeh; Zohreh Habibi; Juan C Fernandez-Miranda; Paul A Gardner; Steven P Hodak; Sue M Challinor
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

5.  SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study.

Authors:  Andrea Giustina; John S Bevan; Marcello D Bronstein; Felipe F Casanueva; Philippe Chanson; Stephan Petersenn; Xuan-Mai Truong Thanh; Caroline Sert; Aude Houchard; Isabelle Guillemin; Shlomo Melmed
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.